Risco de Eventos Cardiovasculares Adversos Maiores em Pacientes com Artrite Reumatoide Tratados com Medicamentos Antirreumáticos Modificadores de Doença Sintéticos Convencionais, Biológicos e Sintéticos Direcionados: Dados observacionais do registro alemão RABBIT
RMD Open 2023;9:e003489 doi 10.1136/rmdopen-2023-003489
This study by Meissner, et al. estimated the effects of JAKi, TNFi, bDMARDs and csDMARDs on the risk of MACE in RA patients. The authors found no significant difference in MACE risk by treatment group, even among patients at increased CV risk.
This cohort study analysed episodes of RA treatments initiated between January 2017 and April 2022 in the RABBIT register. MACE incidence rates and HRs were calculated for the overall patient cohort and for the increased CV risk subgroup.
Keywords:
